Johnson & Johnson: Is The Stock Still Undervalued After The Rally? A Quantitative Approach

Investment Thesis I value Johnson & Johnson (NYSE:JNJ) with a Hold judgment. The company is well-appreciated by investors for being one of the biggest and most diversified players in the pharmaceutical industry, a defensive stock with a long history (62 years) of dividend increase. Given the considerable capital increase the company has been realizing in the last year, this analysis aims to quantitatively evaluate if the company is still undervalued, fairly valued, or overvalued. The outcome of the Monte Ca ...